Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Insider Trading By Ex-FDA Official Puts Spotlight On Agency Practices

This article was originally published in The Tan Sheet

Executive Summary

After Office of Generic Drugs Deputy Director Gordon Johnston left FDA, he joined GPhA and 'tricked' a former colleague into sharing info on generic Lovenox on behalf of a hedge fund he was secretly working for, SEC says.


Related Content

Enoxaparin Generic Saga Continues: Momenta's Manufacturing Patent Invalid
Insider Trading: Ex-Ariad Staffers Charged With Using FDA Info On Iclusig
Managing The World’s First Blockbuster Generic: An Interview With Sandoz’s George
Insider Trading Bull's-Eye: FDA Chemist Charged With Using Agency's DARRTS NDA Tracking System For Improper Trades
FDA Approves Momenta/Sandoz' Lovenox Generic Without Need For Clinical Studies


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts